{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:56:06Z","timestamp":1794362166020,"version":"4.9.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000304","name":"Parkinson's UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022431","name":"Medical Research Council Centre for Neurodevelopmental Disorders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C14\/18\/102"],"award-info":[{"award-number":["C14\/18\/102"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017885","name":"Queen\u00a0Elisabeth\u00a0Medical\u00a0Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017885","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"DOI":"10.1007\/s00401-025-02956-6","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:33:49Z","timestamp":1762853629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The G2019S LRRK2 mutation exacerbates \u03b1-synuclein and tau neuropathology through divergent pathways in Parkinson\u2019s disease models"],"prefix":"10.1007","volume":"150","author":[{"given":"George","family":"Tsafaras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cabezudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lot","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iraklis","family":"Tsakogias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajantha","family":"Abey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Bentea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sanchiz-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Van den Haute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wade-Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Baekelandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"2956_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/FNAGI.2014.00248","author":"JO Aasly","year":"2014","unstructured":"Aasly JO, Johansen KK, Br\u00f8nstad G, War\u00f8 BJ, Majbour NK, Varghese S et al (2014) Elevated levels of cerebrospinal fluid \u03b1-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/FNAGI.2014.00248","journal-title":"Front Aging Neurosci"},{"key":"2956_CR2","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0891-5849(01)00684-0","volume":"31","author":"G Aldini","year":"2001","unstructured":"Aldini G, Yeum KJ, Russell RM, Krinsky NI (2001) A method to measure the oxidizability of both the aqueous and lipid compartments of plasma. Free Radic Biol Med 31:1043\u20131050. https:\/\/doi.org\/10.1016\/S0891-5849(01)00684-0","journal-title":"Free Radic Biol Med"},{"key":"2956_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2018.04.011","volume":"116","author":"MA Andersen","year":"2018","unstructured":"Andersen MA, Christensen KV, Badolo L, Smith GP, Jeggo R, Jensen PH et al (2018) Parkinson\u2019s disease-like burst firing activity in subthalamic nucleus induced by AAV-\u03b1-synuclein is normalized by LRRK2 modulation. Neurobiol Dis 116:13\u201327. https:\/\/doi.org\/10.1016\/j.nbd.2018.04.011","journal-title":"Neurobiol Dis"},{"key":"2956_CR4","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1136\/JCP.41.9.975","volume":"41","author":"GR Armstrong","year":"1988","unstructured":"Armstrong GR, Raafat F (1988) Humoral reaction in the inflamed colon in Hirschsprung\u2019s disease and ulcerative colitis. J Clin Pathol 41:975\u2013977. https:\/\/doi.org\/10.1136\/JCP.41.9.975","journal-title":"J Clin Pathol"},{"key":"2956_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1146\/ANNUREV.CELLBIO.042308.113313","volume":"26","author":"PK Auluck","year":"2010","unstructured":"Auluck PK, Caraveo G, Lindquist S (2010) \u03b1-synuclein: Membrane interactions and toxicity in Parkinson\u2019s disease. Annu Rev Cell Dev Biol 26:211\u2013233. https:\/\/doi.org\/10.1146\/ANNUREV.CELLBIO.042308.113313","journal-title":"Annu Rev Cell Dev Biol"},{"key":"2956_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/FNAGI.2020.630743","author":"J Auzmendi-Iriarte","year":"2021","unstructured":"Auzmendi-Iriarte J, Matheu A (2021) Impact of chaperone-mediated autophagy in brain aging: neurodegenerative diseases and glioblastoma. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/FNAGI.2020.630743","journal-title":"Front Aging Neurosci"},{"key":"2956_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2019.165632","volume":"1866","author":"E-J Bae","year":"2020","unstructured":"Bae E-J, Lee S-J (2020) The LRRK2-RAB axis in regulation of vesicle trafficking and \u03b1-synuclein propagation. Biochim Biophys Acta Mol Basis Dis 1866:165632. https:\/\/doi.org\/10.1016\/j.bbadis.2019.165632","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2956_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1089\/10430340252899019","volume":"13","author":"V Baekelandt","year":"2002","unstructured":"Baekelandt V, Claeys A, Eggermont K, Lauwers E, De Strooper B, Nuttin B et al (2002) Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. Hum Gene Ther 13:841\u2013853. https:\/\/doi.org\/10.1089\/10430340252899019","journal-title":"Hum Gene Ther"},{"key":"2956_CR9","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/S00401-013-1188-4","volume":"126","author":"RM Bailey","year":"2013","unstructured":"Bailey RM, Covy JP, Melrose HL, Rousseau L, Watkinson R, Knight J et al (2013) LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol 126:809\u2013827. https:\/\/doi.org\/10.1007\/S00401-013-1188-4","journal-title":"Acta Neuropathol"},{"key":"2956_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ENE.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Schapira AHV (2020) Parkinson disease. Eur J Neurol 27:27\u201342. https:\/\/doi.org\/10.1111\/ENE.14108","journal-title":"Eur J Neurol"},{"key":"2956_CR11","doi-asserted-by":"publisher","first-page":"214.e1","DOI":"10.1016\/j.neurobiolaging.2018.11.007","volume":"76","author":"C Blauwendraat","year":"2019","unstructured":"Blauwendraat C, Pletnikova O, Geiger JT, Murphy NA, Abramzon Y, Rudow G et al (2019) Genetic analysis of neurodegenerative diseases in a pathology cohort. Neurobiol Aging 76:214.e1-214.e9. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.11.007","journal-title":"Neurobiol Aging"},{"key":"2956_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00401-023-02595-9","volume":"146","author":"D Cabezudo","year":"2023","unstructured":"Cabezudo D, Tsafaras G, Van Acker E, Van den Haute C, Baekelandt V (2023) Mutant LRRK2 exacerbates immune response and neurodegeneration in a chronic model of experimental colitis. Acta Neuropathol 146:245\u2013261. https:\/\/doi.org\/10.1007\/s00401-023-02595-9","journal-title":"Acta Neuropathol"},{"key":"2956_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/BRAIN\/AWAD388","volume":"147","author":"Y Chu","year":"2023","unstructured":"Chu Y, Hirst WD, Federoff HJ, Harms AS, Stoessl AJ, Kordower JH (2023) Nigrostriatal tau pathology in parkinsonism and Parkinson\u2019s disease. Brain 147:444. https:\/\/doi.org\/10.1093\/BRAIN\/AWAD388","journal-title":"Brain"},{"key":"2956_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.nbd.2019.04.005","volume":"127","author":"N Connor-Robson","year":"2019","unstructured":"Connor-Robson N, Booth H, Martin JG, Gao B, Li K, Doig N et al (2019) An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2. Neurobiol Dis 127:512\u2013526. https:\/\/doi.org\/10.1016\/j.nbd.2019.04.005","journal-title":"Neurobiol Dis"},{"key":"2956_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-017-0010-8","volume":"3","author":"DA Cook","year":"2017","unstructured":"Cook DA, Kannarkat GT, Cintron AF, Butkovich LM, Fraser KB, Chang J et al (2017) LRRK2 levels in immune cells are increased in Parkinson\u2019s disease. NPJ Parkinsons Dis 3:11. https:\/\/doi.org\/10.1038\/s41531-017-0010-8","journal-title":"NPJ Parkinsons Dis"},{"key":"2956_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/SCIADV.ABG6677","author":"EJ Cornblath","year":"2021","unstructured":"Cornblath EJ, Li HL, Changolkar L, Zhang B, Brown HJ, Gathagan RJ et al (2021) Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor. Sci Adv. https:\/\/doi.org\/10.1126\/SCIADV.ABG6677","journal-title":"Sci Adv"},{"key":"2956_CR17","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cell.2012.03.037","volume":"149","author":"N Cremades","year":"2012","unstructured":"Cremades N, Cohen SIA, Deas E, Abramov AY, Chen AY, Orte A et al (2012) Direct observation of the interconversion of normal and toxic forms of \u03b1-synuclein. Cell 149:1048\u20131059. https:\/\/doi.org\/10.1016\/j.cell.2012.03.037","journal-title":"Cell"},{"key":"2956_CR18","doi-asserted-by":"publisher","first-page":"19433","DOI":"10.1074\/jbc.M115.660001","volume":"290","author":"JPL Daher","year":"2015","unstructured":"Daher JPL, Abdelmotilib HA, Hu X, Volpicelli-Daley LA, Moehle MS, Fraser KB et al (2015) Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates \u03b1-synuclein gene-induced neurodegeneration. J Biol Chem 290:19433\u201319444. https:\/\/doi.org\/10.1074\/jbc.M115.660001","journal-title":"J Biol Chem"},{"key":"2956_CR19","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1093\/hmg\/dds057","volume":"21","author":"JPL Daher","year":"2012","unstructured":"Daher JPL, Pletnikova O, Biskup S, Musso A, Gellhaar S, Galter D et al (2012) Neurodegenerative phenotypes in an A53T \u03b1-synuclein transgenic mouse model are independent of LRRK2. Hum Mol Genet 21:2420\u20132431. https:\/\/doi.org\/10.1093\/hmg\/dds057","journal-title":"Hum Mol Genet"},{"key":"2956_CR20","doi-asserted-by":"publisher","first-page":"9289","DOI":"10.1073\/pnas.1403215111","volume":"111","author":"JPL Daher","year":"2014","unstructured":"Daher JPL, Volpicelli-Daley LA, Blackburn JP, Moehle MS, West AB (2014) Abrogation of \u03b1-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc Natl Acad Sci U S A 111:9289\u20139294. https:\/\/doi.org\/10.1073\/pnas.1403215111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2956_CR21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/JNC.13712","volume":"138","author":"E Dinter","year":"2016","unstructured":"Dinter E, Saridaki T, Nippold M, Plum S, Diederichs L, Komnig D et al (2016) Rab7 induces clearance of \u03b1-synuclein aggregates. J Neurochem 138:758\u2013774. https:\/\/doi.org\/10.1111\/JNC.13712","journal-title":"J Neurochem"},{"key":"2956_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/FNCEL.2023.1272899\/PDF","author":"N Donison","year":"2023","unstructured":"Donison N, Hintermayer M, Subramaniam M, Santandrea E, Volkening K, Strong MJ (2023) Upregulation of LRRK2 following traumatic brain injury does not directly phosphorylate Thr175 tau. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/FNCEL.2023.1272899\/PDF","journal-title":"Front Cell Neurosci"},{"key":"2956_CR23","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1523\/JNEUROSCI.5092-10.2011","volume":"31","author":"J Dusonchet","year":"2011","unstructured":"Dusonchet J, Kochubey O, Stafa K, Young SM, Zufferey R, Moore DJ et al (2011) A rat model of progressive nigral neurodegeneration induced by the Parkinson\u2019s disease-associated G2019S mutation in LRRK2. J Neurosci 31:907\u2013912. https:\/\/doi.org\/10.1523\/JNEUROSCI.5092-10.2011","journal-title":"J Neurosci"},{"key":"2956_CR24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/mds.26892","volume":"32","author":"N Dzamko","year":"2017","unstructured":"Dzamko N, Gysbers AM, Bandopadhyay R, Bolliger MF, Uchino A, Zhao Y et al (2017) LRRK2 levels and phosphorylation in Parkinson\u2019s disease brain and cases with restricted Lewy bodies. Mov Disord 32:423\u2013432. https:\/\/doi.org\/10.1002\/mds.26892","journal-title":"Mov Disord"},{"key":"2956_CR25","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/mds.26529","volume":"31","author":"N Dzamko","year":"2016","unstructured":"Dzamko N, Rowe DB, Halliday GM (2016) Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. Mov Disord 31:889\u2013897. https:\/\/doi.org\/10.1002\/mds.26529","journal-title":"Mov Disord"},{"key":"2956_CR26","doi-asserted-by":"publisher","first-page":"E9115","DOI":"10.1073\/PNAS.1812196115","volume":"115","author":"T Eguchi","year":"2018","unstructured":"Eguchi T, Kuwahara T, Sakurai M, Komori T, Fujimoto T, Ito G et al (2018) LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis. Proc Natl Acad Sci U S A 115:E9115\u2013E9124. https:\/\/doi.org\/10.1073\/PNAS.1812196115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2956_CR27","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1038\/NPROT.2007.258","volume":"2","author":"MC Fantini","year":"2007","unstructured":"Fantini MC, Dominitzki S, Rizzo A, Neurath MF, Becker C (2007) In vitro generation of cd4+cd25+ regulatory cells from murine naive t cells. Nat Protoc 2:1789\u20131794. https:\/\/doi.org\/10.1038\/NPROT.2007.258","journal-title":"Nat Protoc"},{"issue":"Pt 5","key":"2956_CR28","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley JM, Lees AJ (1991) Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283\u20132301. https:\/\/doi.org\/10.1093\/brain\/114.5.2283","journal-title":"Brain"},{"key":"2956_CR29","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/BIOM5020435","volume":"5","author":"TL da Fonseca","year":"2015","unstructured":"da Fonseca TL, Villar-Piqu\u00e9 A, Outeiro TF (2015) The interplay between alpha-synuclein clearance and spreading. Biomolecules 5:435\u2013471. https:\/\/doi.org\/10.3390\/BIOM5020435","journal-title":"Biomolecules"},{"key":"2956_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0062143","author":"D Freeman","year":"2013","unstructured":"Freeman D, Cedillos R, Choyke S, Lukic Z, McGuire K, Marvin S et al (2013) Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0062143","journal-title":"PLoS One"},{"key":"2956_CR31","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.4049\/jimmunol.1000548","volume":"185","author":"A Gardet","year":"2010","unstructured":"Gardet A, Benita Y, Li C, Sands BE, Ballester I, Stevens C et al (2010) LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol 185:5577\u20135585. https:\/\/doi.org\/10.4049\/jimmunol.1000548","journal-title":"J Immunol"},{"key":"2956_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0896-6273(92)90117-V","volume":"8","author":"M Goedert","year":"1992","unstructured":"Goedert M, Spillantini MG, Cairns NJ, Crowther RA (1992) Tau proteins of Alzheimer\u2019s paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8:159\u2013168. https:\/\/doi.org\/10.1016\/0896-6273(92)90117-V","journal-title":"Neuron"},{"key":"2956_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.nbd.2006.04.001","volume":"23","author":"E Greggio","year":"2006","unstructured":"Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A et al (2006) Kinase activity is required for the toxic effects of mutant LRRK2\/dardarin. Neurobiol Dis 23:329\u2013341. https:\/\/doi.org\/10.1016\/j.nbd.2006.04.001","journal-title":"Neurobiol Dis"},{"key":"2956_CR34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/S00109-012-0984-Y","volume":"91","author":"PS Guerreiro","year":"2013","unstructured":"Guerreiro PS, Huang Y, Gysbers A, Cheng D, Gai WP, Outeiro TF et al (2013) LRRK2 interactions with \u03b1-synuclein in Parkinson\u2019s disease brains and in cell models. J Mol Med 91:513\u2013522. https:\/\/doi.org\/10.1007\/S00109-012-0984-Y","journal-title":"J Mol Med"},{"key":"2956_CR35","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/S12021-016-9303-Z","volume":"14","author":"M Guly\u00e1s","year":"2016","unstructured":"Guly\u00e1s M, Bencsik N, Pusztai S, Liliom H, Schlett K (2016) Animaltracker: an ImageJ-based tracking API to create a customized behaviour analyser program. Neuroinformatics 14:479\u2013481. https:\/\/doi.org\/10.1007\/S12021-016-9303-Z","journal-title":"Neuroinformatics"},{"key":"2956_CR36","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00702-011-0653-2","volume":"118","author":"M Hakimi","year":"2011","unstructured":"Hakimi M, Selvanantham T, Swinton E, Padmore RF, Tong Y, Kabbach G et al (2011) Parkinson\u2019s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm (Vienna) 118:795\u2013808. https:\/\/doi.org\/10.1007\/s00702-011-0653-2","journal-title":"J Neural Transm (Vienna)"},{"key":"2956_CR37","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3233\/JPD-212562","volume":"11","author":"MX Henderson","year":"2021","unstructured":"Henderson MX, Changolkar L, Trojanowski JQ, Lee VMY (2021) LRRK2 kinase activity does not alter cell-autonomous Tau pathology development in primary neurons. J Parkinsons Dis 11:1187\u20131196. https:\/\/doi.org\/10.3233\/JPD-212562","journal-title":"J Parkinsons Dis"},{"key":"2956_CR38","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/s41593-019-0457-5","volume":"22","author":"MX Henderson","year":"2019","unstructured":"Henderson MX, Cornblath EJ, Darwich A, Zhang B, Brown H, Gathagan RJ et al (2019) Spread of \u03b1-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. Nat Neurosci 22:1248\u20131257. https:\/\/doi.org\/10.1038\/s41593-019-0457-5","journal-title":"Nat Neurosci"},{"key":"2956_CR39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40478-019-0679-5","volume":"7","author":"MX Henderson","year":"2019","unstructured":"Henderson MX, Sengupta M, McGeary I, Zhang B, Olufemi MF, Brown H et al (2019) LRRK2 inhibition does not impart protection from \u03b1-synuclein pathology and neuron death in non-transgenic mice. Acta Neuropathol Commun 7:28. https:\/\/doi.org\/10.1186\/s40478-019-0679-5","journal-title":"Acta Neuropathol Commun"},{"key":"2956_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/S40478-019-0836-X","author":"MX Henderson","year":"2019","unstructured":"Henderson MX, Sengupta M, Trojanowski JQ, Lee VMY (2019) Alzheimer\u2019s disease tau is a prominent pathology in LRRK2 Parkinson\u2019s disease. Acta Neuropathol Commun. https:\/\/doi.org\/10.1186\/S40478-019-0836-X","journal-title":"Acta Neuropathol Commun"},{"key":"2956_CR41","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1093\/hmg\/ddv314","volume":"24","author":"AG Henry","year":"2015","unstructured":"Henry AG, Aghamohammadzadeh S, Samaroo H, Chen Y, Mou K, Needle E et al (2015) Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression. Hum Mol Genet 24:6013\u20136028. https:\/\/doi.org\/10.1093\/hmg\/ddv314","journal-title":"Hum Mol Genet"},{"key":"2956_CR42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/15548627.2019.1603545","volume":"16","author":"PWL Ho","year":"2020","unstructured":"Ho PWL, Leung CT, Liu H, Pang SYY, Lam CSC, Xian J et al (2020) Age-dependent accumulation of oligomeric SNCA\/\u03b1-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA). Autophagy 16:347\u2013370. https:\/\/doi.org\/10.1080\/15548627.2019.1603545","journal-title":"Autophagy"},{"key":"2956_CR43","doi-asserted-by":"publisher","unstructured":"Jensen NM, Vitic Z, Antorini MR, Bruun Viftrup T, Parkkinen L, Jensen PH (2024) Abundant non-inclusion \u03b1-synuclein pathology in Lewy body-negative LRRK2-mutant cases. https:\/\/doi.org\/10.1101\/2024.12.20.629583","DOI":"10.1101\/2024.12.20.629583"},{"key":"2956_CR44","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/JAMANEUROL.2014.2704","volume":"72","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW et al (2015) Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 72:100\u2013105. https:\/\/doi.org\/10.1001\/JAMANEUROL.2014.2704","journal-title":"JAMA Neurol"},{"key":"2956_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/FEBS.12579","volume":"281","author":"F Kawakami","year":"2014","unstructured":"Kawakami F, Shimada N, Ohta E, Kagiya G, Kawashima R, Maekawa T et al (2014) Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3\u03b2. FEBS J 281:3\u201313. https:\/\/doi.org\/10.1111\/FEBS.12579","journal-title":"FEBS J"},{"key":"2956_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0030834","author":"F Kawakami","year":"2012","unstructured":"Kawakami F, Yabata T, Ohta E, Maekawa T, Shimada N, Suzuki M et al (2012) LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS ONE. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0030834","journal-title":"PLoS ONE"},{"key":"2956_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105081","author":"T Kuwahara","year":"2020","unstructured":"Kuwahara T, Funakawa K, Komori T, Sakurai M, Yoshii G, Eguchi T et al (2020) Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation. Neurobiol Dis. https:\/\/doi.org\/10.1016\/j.nbd.2020.105081","journal-title":"Neurobiol Dis"},{"key":"2956_CR48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.stem.2018.10.023","volume":"24","author":"C Lang","year":"2019","unstructured":"Lang C, Campbell KR, Ryan BJ, Carling P, Attar M, Vowles J et al (2019) Single-cell sequencing of iPSC-dopamine neurons reconstructs disease progression and identifies HDAC4 as a regulator of Parkinson cell phenotypes. Cell Stem Cell 24:93-106.e6. https:\/\/doi.org\/10.1016\/j.stem.2018.10.023","journal-title":"Cell Stem Cell"},{"key":"2956_CR49","doi-asserted-by":"publisher","first-page":"13138","DOI":"10.1523\/JNEUROSCI.1737-10.2010","volume":"30","author":"CH Lin","year":"2010","unstructured":"Lin CH, Tsai PI, Wu RM, Chien CT (2010) LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3\u03b2. J Neurosci 30:13138\u201313149. https:\/\/doi.org\/10.1523\/JNEUROSCI.1737-10.2010","journal-title":"J Neurosci"},{"key":"2956_CR50","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.neuron.2009.11.006","volume":"64","author":"X Lin","year":"2009","unstructured":"Lin X, Parisiadou L, Gu X-L, Wang L, Shim H, Sun L et al (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson\u2019s-disease-related mutant alpha-synuclein. Neuron 64:807\u2013827. https:\/\/doi.org\/10.1016\/j.neuron.2009.11.006","journal-title":"Neuron"},{"key":"2956_CR51","doi-asserted-by":"publisher","first-page":"2889.e5","DOI":"10.1016\/j.neurobiolaging.2013.04.011","volume":"34","author":"H Ling","year":"2013","unstructured":"Ling H, Kara E, Bandopadhyay R, Hardy J, Holton J, Xiromerisiou G et al (2013) TDP-43 pathology in a patient carrying G2019S LRRK2mutation and a novel p. Q124E MAPT. Neurobiol Aging 34:2889.e5-2889.e9. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2013.04.011","journal-title":"Neurobiol Aging"},{"key":"2956_CR52","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.neuron.2006.10.008","volume":"52","author":"D MacLeod","year":"2006","unstructured":"MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52:587\u2013593. https:\/\/doi.org\/10.1016\/j.neuron.2006.10.008","journal-title":"Neuron"},{"key":"2956_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/S40035-020-00192-4","author":"NK Majbour","year":"2020","unstructured":"Majbour NK, Aasly JO, Hustad E, Thomas MA, Vaikath NN, Elkum N et al (2020) CSF total and oligomeric \u03b1-Synuclein along with TNF-\u03b1 as risk biomarkers for Parkinson\u2019s disease: a study in LRRK2 mutation carriers. Transl Neurodegener. https:\/\/doi.org\/10.1186\/S40035-020-00192-4","journal-title":"Transl Neurodegener"},{"key":"2956_CR54","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1042\/BST20120126","volume":"40","author":"C Manzoni","year":"2012","unstructured":"Manzoni C (2012) LRRK2 and autophagy: a common pathway for disease. Biochem Soc Trans 40:1147\u20131151. https:\/\/doi.org\/10.1042\/BST20120126","journal-title":"Biochem Soc Trans"},{"key":"2956_CR55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/B978-0-323-85555-6.00018-7","volume":"193","author":"I Mata","year":"2023","unstructured":"Mata I, Salles P, Cornejo-Olivas M, Saffie P, Ross OA, Reed X et al (2023) LRRK2: genetic mechanisms vs genetic subtypes. Handb Clin Neurol 193:133\u2013154. https:\/\/doi.org\/10.1016\/B978-0-323-85555-6.00018-7","journal-title":"Handb Clin Neurol"},{"key":"2956_CR56","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106412","volume":"40","author":"D Meng","year":"2021","unstructured":"Meng D, Yang Q, Melick CH, Park BC, Hsieh T-S, Curukovic A et al (2021) Arfgap1 inhibits mTORC1 lysosomal localization and activation. EMBO J 40:e106412. https:\/\/doi.org\/10.15252\/embj.2020106412","journal-title":"EMBO J"},{"key":"2956_CR57","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1093\/HMG\/DDV105","volume":"24","author":"F Mikhail","year":"2015","unstructured":"Mikhail F, Calingasan N, Parolari L, Subramanian A, Yang L, Flint Beal M (2015) Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau. Hum Mol Genet 24:3545\u20133556. https:\/\/doi.org\/10.1093\/HMG\/DDV105","journal-title":"Hum Mol Genet"},{"key":"2956_CR58","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1042\/BCJ20180248","volume":"475","author":"R Mir","year":"2018","unstructured":"Mir R, Tonelli F, Lis P, Macartney T, Polinski NK, Martinez TN et al (2018) The Parkinson\u2019s disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Biochem J 475:1861\u20131883. https:\/\/doi.org\/10.1042\/BCJ20180248","journal-title":"Biochem J"},{"key":"2956_CR59","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coviro.2014.07.004","volume":"8","author":"N Mollentze","year":"2014","unstructured":"Mollentze N, Biek R, Streicker DG (2014) The role of viral evolution in rabies host shifts and emergence. Curr Opin Virol 8:68\u201372. https:\/\/doi.org\/10.1016\/j.coviro.2014.07.004","journal-title":"Curr Opin Virol"},{"key":"2956_CR60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-49969-7_1","volume":"14","author":"E Monfrini","year":"2017","unstructured":"Monfrini E, Di Fonzo A (2017) Leucine-rich repeat kinase (LRRK2) genetics and Parkinson\u2019s disease. Adv Neurobiol 14:3\u201330. https:\/\/doi.org\/10.1007\/978-3-319-49969-7_1","journal-title":"Adv Neurobiol"},{"key":"2956_CR61","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.mad.2013.10.001","volume":"134","author":"EA Nagelhus","year":"2013","unstructured":"Nagelhus EA, Amiry-Moghaddam M, Bergersen LH, Bjaalie JG, Eriksson J, Gundersen V et al (2013) The glia doctrine: addressing the role of glial cells in healthy brain ageing. Mech Ageing Dev 134:449\u2013459. https:\/\/doi.org\/10.1016\/j.mad.2013.10.001","journal-title":"Mech Ageing Dev"},{"key":"2956_CR62","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/HMG\/DDX389","volume":"27","author":"APT Nguyen","year":"2018","unstructured":"Nguyen APT, Daniel G, Vald\u00e9s P, Islam MS, Schneider BL, Moore DJ (2018) G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain. Hum Mol Genet 27:120\u2013134. https:\/\/doi.org\/10.1093\/HMG\/DDX389","journal-title":"Hum Mol Genet"},{"key":"2956_CR63","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.1073\/pnas.1717590115","volume":"115","author":"M Nguyen","year":"2018","unstructured":"Nguyen M, Krainc D (2018) LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson\u2019s disease. Proc Natl Acad Sci U S A 115:5576\u20135581. https:\/\/doi.org\/10.1073\/pnas.1717590115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2956_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-8-44","author":"M Oliveras-Salv\u00e1","year":"2013","unstructured":"Oliveras-Salv\u00e1 M, Van Der Perren A, Casadei N, Stroobants S, Nuber S, D\u2019Hooge R et al (2013) RAAV2\/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Mol Neurodegener. https:\/\/doi.org\/10.1186\/1750-1326-8-44","journal-title":"Mol Neurodegener"},{"key":"2956_CR65","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nn.3350","volume":"16","author":"SJ Orenstein","year":"2013","unstructured":"Orenstein SJ, Kuo S-H, Tasset I, Arias E, Koga H, Fernandez-Carasa I et al (2013) Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 16:394\u2013406. https:\/\/doi.org\/10.1038\/nn.3350","journal-title":"Nat Neurosci"},{"key":"2956_CR66","doi-asserted-by":"publisher","first-page":"13971","DOI":"10.1523\/JNEUROSCI.3799-09.2009","volume":"29","author":"L Parisiadou","year":"2009","unstructured":"Parisiadou L, Xie C, Cho HJ, Lin X, Gu X-L, Long C-X et al (2009) Phosphorylation of ezrin\/radixin\/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 29:13971\u201313980. https:\/\/doi.org\/10.1523\/JNEUROSCI.3799-09.2009","journal-title":"J Neurosci"},{"key":"2956_CR67","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01007-8","author":"A Van der Perren","year":"2021","unstructured":"Van der Perren A, Cabezudo D, Gelders G, Peralta Ramos JM, Van den Haute C, Baekelandt V et al (2021) LRRK2 ablation attenuates \u0391lpha-synuclein-induced neuroinflammation without affecting neurodegeneration or neuropathology in vivo. Neurotherapeutics. https:\/\/doi.org\/10.1007\/s13311-021-01007-8","journal-title":"Neurotherapeutics"},{"key":"2956_CR68","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.neurobiolaging.2014.11.015","volume":"36","author":"A Van der Perren","year":"2015","unstructured":"Van der Perren A, Toelen J, Casteels C, Macchi F, Van Rompuy A-S, Sarre S et al (2015) Longitudinal follow-up and characterization of a robust rat model for Parkinson\u2019s disease based on overexpression of alpha-synuclein with adeno-associated viral vectors. Neurobiol Aging 36:1543\u20131558. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2014.11.015","journal-title":"Neurobiol Aging"},{"key":"2956_CR69","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/MDS.24962","volume":"27","author":"M Poulopoulos","year":"2012","unstructured":"Poulopoulos M, Levy OA, Alcalay RN (2012) The neuropathology of genetic Parkinson\u2019s disease. Mov Disord 27:831\u2013842. https:\/\/doi.org\/10.1002\/MDS.24962","journal-title":"Mov Disord"},{"key":"2956_CR70","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bbrc.2009.06.142","volume":"387","author":"H Qing","year":"2009","unstructured":"Qing H, Wong W, McGeer EG, McGeer PL (2009) Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun 387:149\u2013152. https:\/\/doi.org\/10.1016\/j.bbrc.2009.06.142","journal-title":"Biochem Biophys Res Commun"},{"key":"2956_CR71","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1212\/01.WNL.0000240220.33950.0C","volume":"67","author":"A Rajput","year":"2006","unstructured":"Rajput A, Dickson DW, Robinson CA, Ross OA, D\u00e4chsel JC, Lincoln SJ et al (2006) Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67:1506\u20131508. https:\/\/doi.org\/10.1212\/01.WNL.0000240220.33950.0C","journal-title":"Neurology"},{"key":"2956_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-016-0140-1","volume":"11","author":"DA Roosen","year":"2016","unstructured":"Roosen DA, Cookson MR (2016) LRRK2 at the interface of autophagosomes, endosomes and lysosomes. Mol Neurodegener 11:73. https:\/\/doi.org\/10.1186\/s13024-016-0140-1","journal-title":"Mol Neurodegener"},{"key":"2956_CR73","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.nbd.2017.12.005","volume":"111","author":"J Schapansky","year":"2018","unstructured":"Schapansky J, Khasnavis S, DeAndrade MP, Nardozzi JD, Falkson SR, Boyd JD et al (2018) Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble \u03b1-synuclein in neurons. Neurobiol Dis 111:26\u201335. https:\/\/doi.org\/10.1016\/j.nbd.2017.12.005","journal-title":"Neurobiol Dis"},{"key":"2956_CR74","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1093\/hmg\/ddu138","volume":"23","author":"J Schapansky","year":"2014","unstructured":"Schapansky J, Nardozzi JD, Felizia F, LaVoie MJ (2014) Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. Hum Mol Genet 23:4201\u20134214. https:\/\/doi.org\/10.1093\/hmg\/ddu138","journal-title":"Hum Mol Genet"},{"key":"2956_CR75","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3233\/JPD-181446","volume":"9","author":"A Schildt","year":"2019","unstructured":"Schildt A, Walker MD, Dinelle K, Miao Q, Schulzer M, O\u2019Kusky J et al (2019) Single inflammatory trigger leads to neuroinflammation in LRRK2 rodent model without degeneration of dopaminergic neurons. J Parkinsons Dis 9:121\u2013139. https:\/\/doi.org\/10.3233\/JPD-181446","journal-title":"J Parkinsons Dis"},{"key":"2956_CR76","doi-asserted-by":"publisher","first-page":"W424","DOI":"10.1093\/NAR\/GKW389","volume":"44","author":"D Schneidman-Duhovny","year":"2016","unstructured":"Schneidman-Duhovny D, Hammel M, Tainer JA, Sali A (2016) FoXS, FoXSDock and MultiFoXS: single-state and multi-state structural modeling of proteins and their complexes based on SAXS profiles. Nucleic Acids Res 44:W424\u2013W429. https:\/\/doi.org\/10.1093\/NAR\/GKW389","journal-title":"Nucleic Acids Res"},{"key":"2956_CR77","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/S00401-025-02872-9","volume":"149","author":"H Sekiya","year":"2025","unstructured":"Sekiya H, Franke L, Hashimoto Y, Takata M, Nishida K, Futamura N et al (2025) Widespread distribution of \u03b1-synuclein oligomers in LRRK2-related Parkinson\u2019s disease. Acta Neuropathol 149:42. https:\/\/doi.org\/10.1007\/S00401-025-02872-9","journal-title":"Acta Neuropathol"},{"key":"2956_CR78","doi-asserted-by":"publisher","unstructured":"Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, Casta\u00f1o-D\u00edez D, Schweighauser G, Graff-Meyer A, Goldie KN, S\u00fctterlin R, Huisman E, Ingrassia A, Gier Y de, Rozemuller AJM, Wang J, Paepe A De, Erny J, Staempfli A, Hoernschemeyer J, Gro\u00dfer\u00fcschkamp F, Niedieker D, El-Mashtoly SF, Quadri M, Van Ijcken WFJ, Bonifati V, Gerwert K, Bohrmann B, Frank S, Britschgi M, Stahlberg H, Van de Berg WDJ, Lauer ME (2019) Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes. Nat Neurosci 22:1099\u20131109. https:\/\/doi.org\/10.1038\/S41593-019-0423-2","DOI":"10.1038\/S41593-019-0423-2"},{"key":"2956_CR79","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1021\/ACS.BIOCHEM.5B00326","volume":"54","author":"MR Shanley","year":"2015","unstructured":"Shanley MR, Hawley D, Leung S, Zaidi NF, Dave R, Schlosser KA et al (2015) LRRK2 facilitates tau phosphorylation through strong interaction with tau and cdk5. Biochemistry 54:5198\u20135208. https:\/\/doi.org\/10.1021\/ACS.BIOCHEM.5B00326","journal-title":"Biochemistry"},{"key":"2956_CR80","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA et al (2023) Assessment of heterogeneity among participants in the Parkinson\u2019s progression markers initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol 22:407\u2013417. https:\/\/doi.org\/10.1016\/S1474-4422(23)00109-6","journal-title":"Lancet Neurol"},{"key":"2956_CR81","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.brainres.2018.06.010","volume":"1702","author":"A Singh","year":"2019","unstructured":"Singh A, Zhi L, Zhang H (2019) LRRK2 and mitochondria: recent advances and current views. Brain Res 1702:96\u2013104. https:\/\/doi.org\/10.1016\/j.brainres.2018.06.010","journal-title":"Brain Res"},{"key":"2956_CR82","doi-asserted-by":"publisher","DOI":"10.1017\/S0033583520000025","volume":"53","author":"T Sinnige","year":"2020","unstructured":"Sinnige T, Stroobants K, Dobson CM, Vendruscolo M (2020) Biophysical studies of protein misfolding and aggregation in in vivo models of Alzheimer\u2019s and Parkinson\u2019s diseases. Q Rev Biophys 53:e10. https:\/\/doi.org\/10.1017\/S0033583520000025","journal-title":"Q Rev Biophys"},{"key":"2956_CR83","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","volume":"95","author":"MG Spillantini","year":"1998","unstructured":"Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 95:6469\u20136473. https:\/\/doi.org\/10.1073\/pnas.95.11.6469","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2956_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002526","volume":"8","author":"K Stafa","year":"2012","unstructured":"Stafa K, Trancikova A, Webber PJ, Glauser L, West AB, Moore DJ (2012) GTPase activity and neuronal toxicity of Parkinson\u2019s disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet 8:e1002526. https:\/\/doi.org\/10.1371\/journal.pgen.1002526","journal-title":"PLoS Genet"},{"key":"2956_CR85","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.12813","author":"M Steger","year":"2016","unstructured":"Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M et al (2016) Phosphoproteomics reveals that Parkinson\u2019s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife. https:\/\/doi.org\/10.7554\/eLife.12813","journal-title":"Elife"},{"key":"2956_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021519","volume":"6","author":"J Th\u00e9venet","year":"2011","unstructured":"Th\u00e9venet J, Pescini Gobert R, Hooft van Huijsduijnen R, Wiessner C, Sagot YJ (2011) Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS ONE 6:e21519. https:\/\/doi.org\/10.1371\/journal.pone.0021519","journal-title":"PLoS ONE"},{"key":"2956_CR87","doi-asserted-by":"publisher","first-page":"7871","DOI":"10.1021\/BI030086J","volume":"42","author":"MJ Volles","year":"2003","unstructured":"Volles MJ, Lansbury PT (2003) Zeroing in on the pathogenic form of \u03b1-synuclein and its mechanism of neurotoxicity in Parkinson\u2019s disease. Biochemistry 42:7871\u20137878. https:\/\/doi.org\/10.1021\/BI030086J","journal-title":"Biochemistry"},{"key":"2956_CR88","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1523\/JNEUROSCI.3642-15.2016","volume":"36","author":"LA Volpicelli-Daley","year":"2016","unstructured":"Volpicelli-Daley LA, Abdelmotilib H, Liu Z, Stoyka L, Daher JPL, Milnerwood AJ et al (2016) G2019S-LRRK2 expression augments \u03b1-synuclein sequestration into inclusions in neurons. J Neurosci 36:7415\u20137427. https:\/\/doi.org\/10.1523\/JNEUROSCI.3642-15.2016","journal-title":"J Neurosci"},{"key":"2956_CR89","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/S12035-012-8280-Y","volume":"47","author":"K Wakabayashi","year":"2013","unstructured":"Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H (2013) The Lewy body in Parkinson\u2019s disease and related neurodegenerative disorders. Mol Neurobiol 47:495\u2013508. https:\/\/doi.org\/10.1007\/S12035-012-8280-Y","journal-title":"Mol Neurobiol"},{"key":"2956_CR90","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/15548627.2019.1603548","volume":"16","author":"F Wauters","year":"2020","unstructured":"Wauters F, Cornelissen T, Imberechts D, Martin S, Koentjoro B, Sue C et al (2020) LRRK2 mutations impair depolarization-induced mitophagy through inhibition of mitochondrial accumulation of RAB10. Autophagy 16:203\u2013222. https:\/\/doi.org\/10.1080\/15548627.2019.1603548","journal-title":"Autophagy"},{"key":"2956_CR91","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1093\/hmg\/ddad102","volume":"32","author":"MG Williamson","year":"2023","unstructured":"Williamson MG, Madureira M, McGuinness W, Heon-Roberts R, Mock ED, Naidoo K et al (2023) Mitochondrial dysfunction and mitophagy defects in LRRK2-R1441C Parkinson\u2019s disease models. Hum Mol Genet 32:2808\u20132821. https:\/\/doi.org\/10.1093\/hmg\/ddad102","journal-title":"Hum Mol Genet"},{"key":"2956_CR92","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1073\/PNAS.1100976108\/-\/DCSUPPLEMENTAL\/PNAS.201100976SI.PDF","volume":"108","author":"B Winner","year":"2011","unstructured":"Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S et al (2011) In vivo demonstration that \u03b1-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108:4194\u20134199. https:\/\/doi.org\/10.1073\/PNAS.1100976108\/-\/DCSUPPLEMENTAL\/PNAS.201100976SI.PDF","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2956_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-019-13413-W","author":"D Ysselstein","year":"2019","unstructured":"Ysselstein D, Nguyen M, Young TJ, Severino A, Schwake M, Merchant K et al (2019) LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson\u2019s disease patients. Nat Commun. https:\/\/doi.org\/10.1038\/S41467-019-13413-W","journal-title":"Nat Commun"},{"key":"2956_CR94","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/hmg\/ddz038","volume":"28","author":"F Zambon","year":"2019","unstructured":"Zambon F, Cherubini M, Fernandes HJR, Lang C, Ryan BJ, Volpato V et al (2019) Cellular \u03b1-synuclein pathology is associated with bioenergetic dysfunction in Parkinson\u2019s iPSC-derived dopamine neurons. Hum Mol Genet 28:2001\u20132013. https:\/\/doi.org\/10.1093\/hmg\/ddz038","journal-title":"Hum Mol Genet"},{"key":"2956_CR95","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3389\/FNEUR.2018.00809","volume":"9","author":"X Zhang","year":"2018","unstructured":"Zhang X, Gao F, Wang D, Li C, Fu Y, He W et al (2018) Tau pathology in Parkinson\u2019s disease. Front Neurol 9:809. https:\/\/doi.org\/10.3389\/FNEUR.2018.00809","journal-title":"Front Neurol"},{"key":"2956_CR96","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.omtn.2021.08.001","volume":"25","author":"HT Zhao","year":"2021","unstructured":"Zhao HT, John N, Delic V, Ikeda-Lee K, Kim A, Weihofen A et al (2021) Erratum: LRRK2 antisense oligonucleotides ameliorate \u03b1-synuclein inclusion formation in a Parkinson\u2019s disease mouse model. Mol Ther Nucleic Acids 25:152\u2013154","journal-title":"Mol Ther Nucleic Acids"},{"key":"2956_CR97","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","volume":"44","author":"A Zimprich","year":"2004","unstructured":"Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601\u2013607. https:\/\/doi.org\/10.1016\/j.neuron.2004.11.005","journal-title":"Neuron"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-025-02956-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-025-02956-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-025-02956-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:33:51Z","timestamp":1762853631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-025-02956-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2956"],"URL":"https:\/\/doi.org\/10.1007\/s00401-025-02956-6","relation":{},"ISSN":["1432-0533"],"issn-type":[{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were carried out in accordance with the European Communities Council Directive of November 24, 1986 (86\/609\/EEC) and approved by the Bioethical Committee of the KU Leuven (Belgium) (ECD projects 051\/2020 and 156\/2022). Participants were recruited to the Discovery clinical cohort through the Oxford Parkinson\u2019s Disease Center and gave signed informed consent to mutation screening and derivation of iPSC lines from skin biopsies (Ethics committee: National Health Service, Health Research Authority, NRES Committee South Central, Berkshire, UK, REC 10\/H0505\/71).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors consent to the publication. Manuscript was read and approved by all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analyzed during this study is included in this published article [and its supplementary information files].","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}